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A Core Outcome Set and minimum reporting set for
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BACKGROUND: Different interventions and treatments are available for growth-restricted newborns to improve neonatal and long-
term outcomes. Lack of outcome standardization across trials of feeding interventions limits pooled analysis of intervention effects.
This study aimed to develop a core outcome set (COS) and minimum reporting set (MRS) for this research field.
METHODS: A scoping search identified relevant outcomes and baseline characteristics. These outcomes were presented to two
stakeholder groups (lay experience and professional experts) in three rounds of online Delphi surveys. The professional experts
were involved in the development of the MRS. All items were rated for their importance on a 5-point Likert scale and re-rated in
subsequent rounds after presentation of the results at the group level. During a face-to-face consensus meeting the final COS and
MRS were determined.
RESULTS: Forty-seven of 53 experts (89%) who completed the first round completed all three survey rounds. After the consensus
meeting, consensus was reached on 19 outcomes and 17 baseline characteristics.
CONCLUSIONS: A COS and MRS for feeding interventions in the newborn after growth restriction were developed. Use of these
sets will promote uniform reporting of study characteristics and improve data synthesis and meta-analysis of multiple studies.
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IMPACT:
● Both a COS and MRS for growth restriction in the newborn were developed.
● This study provides the first international combined health-care professional and patient consensus on outcomes and baseline
characteristics for intervention and treatment studies in growth-restricted newborns.
● The use of COS and MRS results in the development of more uniform study protocols, thereby facilitating data synthesis/meta-
analysis of multiple studies aiming to optimize treatment and interventions in growth restriction in the newborn.
INTRODUCTION
Growth restriction in the newborn (GRN) is the newborn
equivalent of fetal growth restriction (FGR).1 Suboptimal growth
is associated with poor outcomes regardless of the timing of
diagnosis.2–4 After the birth of a growth-restricted newborn,
different interventions and treatments, predominantly feeding
strategies, have been described and each of these interventions
has its own/specific benefits and risks.5–8 Positive immediate
effects of successful feeding, such as accelerated (“catch-up”)
growth, can, however, have a potential negative trade-off for
metabolic health, including a higher risk of obesity and
cardiovascular disease.9–12 Given the increased risk for neonatal
morbidity and mortality in GRN and the increased risk for poor
neurodevelopmental outcomes later in life, evidence is needed on
the most effective and safest interventions and treatments for
these growth-restricted newborns.
Comparing results from interventional and treatment studies
concerning GRN is hampered due to the use of different baseline
characteristics and, equally important, differences in reported
study outcomes.13 In order to be able to compare study results
and to allow pooling of data, more and more attention is paid to
the development and use of core outcome sets (COSs). The value
of COSs can be greatly enhanced by adding a set of essential
baseline characteristics to report, often referred to a minimum
reporting set (MRS), in order to align knowledge about details of
the study populations and circumstances.14 COSs are agreed,
clearly defined, minimum sets of outcomes that can be measured
in a standardized manner and reported consistently.15 Standardi-
zation of outcomes for clinical trials ought to prevent the
problems of inappropriate and non-uniform outcome selection
and reporting bias.15,16 Both an MRS and a COS have already been
developed for FGR.14,17
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The aim of this study was to develop both a COS and an MRS for
GRN using the Delphi methodology engaging key stakeholders.
METHODS
The international steering group consisted of healthcare profes-
sionals, researchers, and patient representatives. A protocol with
explicitly defined objectives, consensus methods, participant
recruitment, and statistical methods was developed and prospec-
tively registered at the Core Outcome Measures in Effectiveness
Trials (COMET) initiative (registration number: 1001) and pub-
lished.18,19 The ethical board of the University Medical Center of
Groningen provided a waiver of an ethical approval procedure
(reference number: METc 2018.624).
Scope
Both the COS and MRS apply to postnatal non-invasive
therapeutic interventions and treatments for growth-restricted
newborns, either diagnosed antenatally (FGR) or at birth (GRN),
defined according to international consensus definitions.1,20 Both
sets concern the specific items of growth restriction, regardless of
gestational age. For preterm birth a COS has already been
developed.21
Literature search
A scoping literature review was performed for published literature
on intervention and treatment studies of GRN in PubMed from
2008 to June 2018 with search terms diet therapy (nutritional
management, feeding, diet, diet therapy) and fetal growth
retardation (small for gestational age, SGA, intrauterine growth
restriction, very low birth weight, fetal growth restriction, FGR,
growth-restricted fetuses, fetal growth retardation). Titles and
abstracts of clinical trials were screened and baseline character-
istics and reported outcomes were extracted. Articles were
included if they concerned term and/or preterm GRN and
nutritional management intervention. Exclusion criteria were
articles concerning preterm but not specifically growth-restricted
newborns, treatment by hormones or medication, parentally
administered treatment, or when the article was not available in
English. Any discrepancies were resolved by discussion within the
steering group.
Stakeholders
Two stakeholder groups were involved in this study: a lay expert
group consisting of patient representatives and parents of
growth-restricted newborns, and a stakeholder group consisting
of professional experts, including neonatologists, (general) pedia-
tricians, obstetricians, and researchers with a special interest in
GRN.1 Lay experts were approached through patient forums and
through posters and flyers that were displayed in the public areas
of participating hospitals (obstetric and pediatric wards as well as
the Neonatal Intensive Care Units), general practitioner practices,
and midwifery clinics located in the Netherlands and in London.
The poster and flyer material contained both a link and QR code to
subscribe to the procedure and a link to a short video with
explanations in plain language of the background and aim of the
project by a neonatologist (F.H.B.). All communication was in
English.
Delphi study
An electronic three-round survey was performed, in which the
Delphi consensus methodology was applied; details of the
planned procedure have been published.19 The Delphi procedure
aims for convergence of opinions resulting in consensus of
participants by multiple rounds, wherein statements are weighed,
summarized, and fed back at the stakeholder level (individual
answers are anonymous).22 The survey was subdivided into a
procedure to come to a COS and one to come to an MRS. In the
latter, only professional experts were involved. Both the COS and
MRS were structured into several domains. A description in plain
language of each outcome was provided in the online surveys.
In the first round, all participants were asked to rate the
importance of each outcome on a 5-point Likert scale anchored
between 1 (very unimportant) and 5 (very important). For the
development of the MRS, only the professional experts were asked
to rate the importance of each baseline characteristic. The
predefined cut-off for inclusion was a median Likert score of 5.
All participants could suggest additional outcomes and profes-
sional experts were also asked to recommend additional missing
baseline characteristics. Outcomes and baseline characteristics
suggested at least twice by individual participants were reviewed
by the steering group for presentation in the next round.
In the second round, the medians of all outcomes were
presented at the stakeholder group level. Participants were asked
to reflect their opinion of the importance of each outcome in the
light of these results and possible differences between the
stakeholder groups and to score each outcome again. Professional
experts were also asked to re-rate each baseline characteristic with
the medians of all baseline characteristics, presented at the group
level, in mind.
In the third round, outcomes were presented to confirm
inclusion when >70% of both panels scored an outcome Likert
score of 5 and ≤15% of both panels scored an outcome Likert
score of 1, or when >90% of a single panel scored an outcome
Likert score of 5. Baseline characteristics were presented to
confirm inclusion when >70% of the experts scored a character-
istic Likert score of 5. Outcomes and baseline characteristics that
did not meet the predefined criteria as described above were
presented for verification of exclusion.
The results of the Delphi survey were discussed in a face-to-face
consensus meeting organized as a satellite to a large international
meeting in order to achieve an international representation of
participants. All participants received a summary of the results of
round 3 prior to the meeting. The meeting was chaired by a non-
voting member of the steering committee with expertise in the
development of a COS (W.G.). Outcomes identified in round 3 of
the Delphi as having reached consensus for inclusion were
presented first and participants were asked if there were any
fundamental reasons why these should not be included in the
COS. All outcomes for which no consensus was reached were
discussed and voted on, one item at a time. The chair ensured all
participants had an equal opportunity to contribute before voting
commenced. The consensus was defined with a pre-set level of
agreement of five out of six participants (>83% agreement) to
finalize the COS and three out of three participants (100%) in the
procedure to finalize the MRS. Consensus rules were strictly
adhered to and, following discussion, voting was done anon-
ymously with blinded jars that collected masked papers with “yes”
and “no”.
The final COS was presented to all participants who completed
round 3 and they were asked to indicate whether they agreed
upon the eventual set of outcomes. The same principle was
applied for the MRS in which the professional experts could agree
or disagree upon the set of characteristics. In case of disagreement
on a specific outcome or baseline characteristic, the participants
were asked to provide a reason.
Data collection
Data were collected using online questionnaires. The responses
were captured in the online REDCap tool, version 7.3.2. Every
participant received a unique token-secured link to participate in
the online survey. Participants received at least two reminder
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emails, and non-responders were excluded from subsequent
survey rounds.
RESULTS
The PubMed scoping search yielded 19 clinical intervention trials.
One hundred and sixty-four outcomes were identified and 121
baseline characteristics (Fig. 1). After checking with the steering
group for relevance to the study population, missing items,
doubling, and overlap, 77 outcomes and 48 baseline character-
istics were grouped into domains and presented to the
stakeholders in the online survey rounds.
One hundred and fifty-one invitations were sent in the first
round, of which 111 were for participants who had registered their
interest for the procedure and 40 professional experts were
approached directly and invited to participate. Fifty-three
participants completed the first round, of whom 34 were
professional experts and 19 were parents of GRN. A total of 47
participants (88.7%) completed all three rounds. Demographic
characteristics of these participants are shown in Table 1a, b.
In the first round, 13 outcomes were scored a median Likert
score of 5 (very important) by the parents and 25 outcomes were
scored a median Likert score of 5 by the professional experts.
Twenty-four baseline characteristics scored a median Likert score
of 5. No new outcomes or baseline characteristics were added
after round 1 as none of the suggestions was mentioned by two or
more individual participants. In the two subsequent electronic
rounds, all outcomes and baseline characteristics were brought
back for consensus on inclusion. Ultimately, a total of 16 outcomes
and 20 baseline characteristics met the criteria for inclusion after
round 3 (Fig. 2).
The face-to-face consensus meeting was held as a satellite
meeting to the joint European Neonatal Societies (jENS) con-
ference in Maastricht, the Netherlands on 21 September 2019.
Three participants from each stakeholder group and from four
countries participated. Consensus decisions made during this
meeting are shown in Supplementary Table S1. The final COS
includes 19 outcomes across eight domains (Table 2) and the final
MRS includes 17 baseline characteristics across five domains
(Table 3). Outcomes and baseline characteristics not included in
the eventual sets are shown in Supplementary Tables S2 and S3.
The consultation round was completed by 45 (95.7%) of the
participants completing round 3, of whom 41 (91.1%) agreed with
the final COS and 30 (93.8%) of the 32 expert professionals agreed
with the final MRS.
DISCUSSION
A COS and an MRS for intervention and treatment studies in GRN
were developed using the Delphi consensus methodology. They
consist of 19 outcomes and 17 baseline characteristics, respec-
tively. Both outcomes and baseline characteristics can be used in
the development of future study protocols, conduction of reviews,
and guidelines on GRN. It is important to note that COS and MRS
represent the minimum set of outcomes and baseline character-
istics that should be reported in all trials on that specific research
topic. The list is not exhaustive and additional outcomes and
baseline characteristics should be freely reported if deemed
relevant.15
The COS captures meaningful outcomes of GRN, including
morbidity of several organ tracts, growth, mortality, and long-term
follow-up. Some of the included outcomes merit further explana-
tion. First, periventricular leukomalacia (PVL) is hard to measure
and needs extra investigations in the newborn. Inclusion of PVL
should not oblige future studies to perform standard investiga-
tions to assess PVL, but should be measured and reported when
undertaken as part of the study and, when not assessed, this
should be stated. Second, the outcomes “hospital stay” and “NICU
stay” are subject to significant practice variation and to factors
that are not strictly related to the disease burden of the newborn.
For example, cesarean section prolongs maternal hospital stay
(and thus neonatal hospital stay regardless of the neonatal
condition) compared to vaginal birth, and different newborn
services will have different policies and protocols about when to
admit babies to the nursery. Therefore, researchers are encour-
aged to report the indication(s) for neonatal “hospital stay” and
“NICU stay” recognizing that they are strongly correlated, but are
considered to cover a slightly different representation of the
disease burden. After lengthy discussions during the consensus
meeting, it was decided to include both outcomes “hospital stay”
and “NICU stay” as these are easy to measure and provide insight
into the circumstances of the study, the intervention results, and
potential cost savings.
One of the included outcomes is breastfeeding, indicating
that for both healthcare experts and patients whether or not the
infant is (fully) breastfed during and/or after interventions and
treatments is considered very important. Of note, the baseline
characteristic “intends to breastfeed” was voted out from the
MRS. However, it was discussed that the MRS represents a
minimum of what should be reported at baseline in all studies
on GRN. Another baseline characteristic not included was the
“use of assisted reproductive technology” (ART) because these
data may be challenging to report reliably, although the
literature suggests that certain variables in ART might influence
birth weight.23,24 Reporting this baseline might be considered if
deemed relevant.
Strengths and limitations
For the development of the COS, the guidelines outlined by the
COMET initiative were used.18
PubMed search n = 204
Excluded based on title and abstract n = 94
Excluded based on full text n = 91
Not growth restricted n = 73
Parenteral administration n = 12
Medication n = 2
Duplicate n = 1
No nutritional management n = 3
Screening title and abstract
Full-text articles reviewed n = 110
Included clinical trials for reporting outcomes and
baseline characteristics
n = 19
Fig. 1 Flow chart of study selection. Flow chart of study selection for identifying outcomes and baseline characteristics.
A Core Outcome Set and minimum reporting set for intervention studies in. . .
SE Damhuis et al.
3
Pediatric Research _#####################_
Recruitment of parents and patient representatives occurred via
posters, patient forums, folders, and newsletters of patient
representatives. This form of recruitment led to an almost 100%
representation of Dutch participants in the patient stakeholder
group. Despite the potential risk of selection bias due to possible
higher educational level, the fact that lay experts were involved as
stakeholder group was considered as an important strength of the
study. Lay expert involvement is a crucial contribution in
developing a COS as outcomes that are most relevant to patients
or carers, the ones who actually feel the burden and benefits of
the interventions and treatments, should be included.18 The
scores of both stakeholder groups were weighed equally even
though the number of participating lay experts was smaller than
the number of participating professional experts.
Another limitation is the limited number of participants in the
face-to-face meeting. This was due to the requirement of equal
representation of both stakeholder groups and the inability to
achieve attendance of more than three lay experts. We think that
this limitation was significantly attenuated by the high agreement
in the online panel of participants in the consultation round.
A scoping review instead of a systematic review was performed
with the rationale that an outcome that is hardly ever reported is
unlikely to be part of a COS. This rationale was strengthened by
the fact that although participants were asked to suggest
additional outcomes and baseline characteristics not listed in
the initial list of outcomes and baseline characteristics, no
consistent additional suggestions were made. Pre-set inclusion
rules allowed that when >90% of one of the stakeholder groups
scored an outcome Likert score of 5, it would be taken forward as
an inclusion to the next round, regardless of the other stakeholder
group score.
Due to financial constraints, only a face-to-face consensus
meeting was held (and no additional electronic meeting as
planned in the protocol).
Final COS/MRS
During the consensus meeting, three outcomes were added to the
final COS and one outcome “hypoxic–ischemic encephalopathy
(HIE)” was considered to be a baseline characteristic as it happens
prior to, during, or shortly after birth, and is thus either present or
absent in the growth-restricted newborn. HIE was previously
included as an outcome in the developed COS for the antenatally
detected growth restriction.17 Two baseline characteristics (pre-
mature rupture of membranes and placental abruption) were
excluded from the final COS as both were not considered to
provide relevant information about the effect of treatments
in GRN.
Both the final COS and MRS corresponds largely with the
previously developed COS and MRS for FGR.17 Some baseline
characteristics incorporated in the current MRS were included as
outcomes in the COS of FGR, which is logical as the change of
outcome to baseline characteristic is at birth. For example, birth
weight is an outcome in the antenatal diagnosis of FGR, but a
baseline characteristic in GRN. Since GRN is the postpartum
equivalent of FGR, the alignment of these sets enables future
studies to compare data deriving from the same pathological
condition, but investigated at different moments (antenatal and
postnatal).
Round 1
Parents: 13 outcomes median Likert 5
16 outcomes to present for inclusiona
16 outcomes considered includedc
Final COS: 19 outcomese
91% agreement 94% agreement
Experts: 25 outcomes median Likert 5
COS
77 outcomes presented
MRS (experts only)
48 baseline characteristics presented
24 baseline characteristics median
Likert 5
20 baseline characteristics to present
for inclusionb
20 baseline characteristics considered
inclusiond
Final MRS: 17 baseline characteristicsf
53 completed responses
(19 parents⎪34 professional experts)
Round 2
48 completed responses (91%)
(15 parents⎪33 professional experts)
Round 3
47 completed responses (98%)
(14 parents⎪33 professional experts)
Face-to-face consensus meeting
6 participants
(3 parents⎪3 professional experts)
Consultation round
45 completed responses (96%)
(13 parents⎪32 professional experts)
Fig. 2 Summary of study methods and results. aBoth stakeholder groups >70% with a Likert score of 5 and <15% with a Likert score of 1 OR
one stakeholder group >90% with a Likert score of 5. bGreater than 70% with a Likert score of 5 and <15% with a Likert score of 1 (professional
experts only). cAgreement on inclusion >70 in both stakeholder groups or >90% in one stakeholder group. dAgreement on inclusion >70%
(professional experts only). eConsensus criteria: five out of six agreement (>83%). fConsensus criteria: three out of three agreement (100%).
A Core Outcome Set and minimum reporting set for intervention studies in. . .
SE Damhuis et al.
4
Pediatric Research _#####################_
Interpretation
The COS and MRS are the minimum of what should be reported in
future studies focused on GRN and can be used as a framework for
the outcome and baseline characteristic selection. Future work will
focus on how these outcomes should be defined and reported.
Until further data are available, we encourage researchers to
clearly report the measures that they have used. In our opinion,
outcomes included in a COS are not mandatory to be measured if
for that study specifically it is unfeasible; however, if measured or
assessed for clinical reasons, the outcome should be reported. If
not assessed, it should be indicated why the outcome is not
applicable for transparency and to reduce the risk of
reporting bias.
Table 3. Final MRS to be reported in all studies on GRN.
Domain Baseline characteristic
Maternal baseline characteristics Age (years)
BMI (pre-pregnancy or first trimester)
Highest level of education
Obstetric information Substance abuse during pregnancya
Complications antenatal Congenital infection likely to affect
fetal growth
Hypertensive disorders during pregnancyb
General information postpartum Antenatally detected fetal growth restriction
Birth weight (g)
Gestational age at the time of delivery
Sex of the newborn
(Part of ) multiple pregnancy
Mode of birth
Chromosomal abnormalities
Congenital anomalies likely to affect
fetal growth
Head circumference at birth (cm)
Length at birth (cm)
Fetal baseline characteristic Hypoxic–ischemic encephalopathy
aSmoking, alcohol, and drugs.
bIncluding gestational hypertension, preeclampsia, and Hemolysis,
Elevated Liver enzymes, and Low Platelets syndrome (HELLP).
Table 1. (a) Characteristics of lay experts (patient representatives and
parents of a growth-restricted newborn) who completed all three
online rounds. (b) Characteristics of professional experts who
completed all three online rounds.
Number Percent
(a) Parent characteristics
Sex
Male 2 14.3
Female 12 85.7
Region of domicile
Europe 14 100.0
North America 0 0
South America 0 0
Asia/Australia 0 0
Africa 0 0
Time since GRN was born
<5 years 10 71.4
5–10 years 2 14.3
10–15 years 0 0
>15 years 2 14.3
(b) Professional experts’ characteristics
Occupation
Neonatologist 25 75.8
(General) pediatrician 3 9.1
Obstetrician/gynecologist 3 9.1
Researcher 2 6.1
Sex
Male 16 48.5
Female 17 51.5
Country of practice
Europe 22 66.7
North America 5 15.2
South America 0 0
Asia/Australia 6 18.2
Africa 0 0
Professional position
Professor 12 36.4
Associate professor 7 21.2
Assistant professor 0 0
Consultant/medical specialist 13 39.4
Fellow 0 0
Registrar/trainee 1 3.0
Non-clinical investigator/researcher 0 0
Midwife 0 0
Other 0 0
Years of practice in current function
0–4 years 1 3.0
5–9 years 10 30.3
10–20 years 9 27.3
>20 years 13 39.4
Tertiary referral center for FGR/GRN
Yes 28 84.8
No 5 15.2
Annual births at expert’s center
<1000 0 0
1000–2500 9 27.3
2500–5000 9 27.3
>5000 12 36.4
Unknown 3 9.1
GRN treated by individual expert on annual base
<5 0 0
5–15 1 3.0
15–25 5 15.2
>25 20 60.6
None 2 6.1
Table 2. Final COS to be included in all studies on GRN.
Domain Outcome
Gastrointestinal Necrotizing enterocolitis
Need for gastrointestinal surgery
Respiratory Bronchopulmonary dysplasia
Neurological Intraventricular hemorrhage
Periventricular leukomalacia
Infection Sepsis
Feeding Breastfeeding
Hospital and mortality Duration of stay in a newborn nursery (days)
Hospital stay (days)
Need for neonatal intensive care
Neonatal mortality
Growth/weight Head circumference
Length
Weight gain
Long-term follow-up Cerebral palsy
Cognitive impairment
Hearing impairment
Motor impairment
Visual impairment
A Core Outcome Set and minimum reporting set for intervention studies in. . .
SE Damhuis et al.
5
Pediatric Research _#####################_
Of note, it is essential that trial populations of fetal and neonatal
growth are critically reviewed for their definition of the diagnosis,
along with the use of the developed COS and MRS. In the absence
of a golden standard to diagnose FGR and GRN, inconsistency in
definitions is a problem in interpreting and comparing data. To
overcome heterogeneous defining and reporting of the diagnosis,
international consensus definitions were developed. Current sets
apply to growth-restricted newborns defined according to these
international consensus definitions.1,20
CONCLUSION
In the COSNEON procedure both a COS and an MRS were
developed that, as a minimum, should be collected in future
studies with a focus on GRN. This will help standardize reporting
on this topic and facilitate the comparison of data across studies
to guide clinical practice.
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